Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2021

View Archived Issues

Potent antiobesity effect seen with ZP-8396 in combination with semaglutide

SP-101 administration restores airway epithelial function in cystic fibrosis

ELD-607 reduces pulmonary inflammation and lung damage in vivo

Chengdu Baiyu Pharmaceutical patents DNA-PK inhibitors

Beijing Scitech-Mq Pharmaceuticals divulges EGFR and/or HER2 inhibitors

Qilu Pharmaceutical presents EGFR inhibitors for lung cancer

BPN-15477 corrects splicing defect caused by the c.2988G>A variant in CFTR

Teijin Pharma and Amgen synthesize TRPC6 antagonists

Japanese researchers disclose new SPR inhibitors

Parkinson's disease model confirms metabolic, contests anatomic tenets

MM-3122, a novel TMPRSS2 inhibitor with antiviral activity against SARS-CoV-2 and MERS-CoV

Vyne reports preclinical data on effect of VYN-201 on skin healing and repair

F508del and G542X cystic fibrosis sheep models exhibit severe phenotype

GABAergic interneuron progenitors from iPSCs improve signs of experimental Alzheimer's disease

TT-10-loaded nanoparticles enhance cardiac function in murine model of myocardial infarction

Discovery of HB-007, a small-molecule degrader of SUMO1

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...